Management of Hyperkalemia with Lokelma

Indications and Clinical Scenarios

The European Society of Cardiology recommends starting potassium-lowering agents like Lokelma when potassium rises above 5.0 mEq/L in patients receiving maximum-tolerated RAAS inhibitor doses, allowing maintenance of cardioprotective therapy 1, 2
Initiate Lokelma when potassium >5.0 mEq/L in patients on RAAS inhibitors to enable continuation of these life-saving medications 1, 3, 4
For patients with potassium 5.0-6.5 mEq/L on RAAS inhibitors, initiate Lokelma while maintaining RAAS inhibitor therapy unless an alternative treatable cause is identified 2, 5

Sodium zirconium cyclosilicate reduces serum potassium within 1 hour of a single 10g dose and is effective for both acute and chronic management 6, 2
In emergency department patients with potassium ≥5.8 mEq/L, SZC 10g (3 doses in 10 hours) reduced mean serum potassium by 0.72 mEq/L within 2 hours 6

Check serum potassium within 1 week of starting Lokelma, then reassess at 1-2 weeks, 3 months, and every 6 months thereafter 2
Monitor closely for hypokalemia, which may be even more dangerous than hyperkalemia, particularly in hemodialysis patients 2

Patients with advanced CKD (stage 4-5) tolerate higher potassium levels (3.3-5.5 mEq/L) due to compensatory mechanisms, but maintaining target potassium 4.0-5.0 mEq/L minimizes mortality risk 6, 2
The 2022 AHA/ACC/HFSA guidelines note that while patiromer and SZC lower potassium levels, their effectiveness in improving clinical outcomes by facilitating continuation of RAASi therapy remains uncertain 4

Lokelma has faster onset (1 hour) compared to patiromer (7 hours), making it preferable for more urgent outpatient scenarios 1, 2
Both patiromer and SZC are superior to sodium polystyrene sulfonate (Kayexalate), which has limited efficacy data and serious gastrointestinal adverse effects including bowel necrosis 1, 3, 2

Begin Lokelma when serum potassium exceeds 5.0 mmol/L in kidney‑transplant recipients who are on optimized therapy, aligning with the European Society of Cardiology (ESC) recommendation to continue RAAS‑inhibitor treatment in this range. This guidance is based on ESC guideline evidence (high‑quality). 7

Do not discontinue RAAS inhibitors prematurely when potassium is between 5.0–5.5 mmol/L; instead, start Lokelma to preserve cardioprotective therapy, as advised by the ESC guidelines (high‑quality evidence). 7

The ESC guideline is cited as the highest‑quality evidence supporting Lokelma use in this setting, superseding lower‑level sources such as FDA labeling summaries. 7